CNS Pharmaceuticals, Inc. Current Assets
CNS Pharmaceuticals, Inc. (CNSP) had Current Assets of $21.92 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-12
- 2026-06-30: Assets, Current $21.92M.
- 2026-03-31: Assets, Current $4.08M.
- 2025-12-31: Assets, Current $8.10M; Assets, Current as first filed $8.10M.
- 2025-09-30: Assets, Current $11.39M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $21.92M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $4.08M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $8.10M 10-Q · filed 2026-08-12 | $8.10M 10-K · filed 2026-03-31 |
| 2025-09-30 | $11.39M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $14.14M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $13.72M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $8.66M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $7.39M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $2.15M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $1.60M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $1.59M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $2.06M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $6.07M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $6.97M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $12.56M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $8.70M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $11.40M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $14.73M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $7.48M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $11.16M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $13.88M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $12.79M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $15.50M 10-K · filed 2022-03-03 | |
| 2020-09-30 | $2.52M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $3.95M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $6.19M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | $7.89M 10-K · filed 2021-02-12 | |
| 2019-09-30 | $1.39M 10-Q · filed 2019-12-20 | |
| 2018-12-31 | $588.13K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |